Biotech

Companies & Industries News

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 27.04.2022.

#BioSpace
#Lance
#BiotechBrief
#biopharma
#covidnews
#BlackDiamondTherapeutics
#Saniona
#BDO
#bioscience
#neurology

Companies And Industries

@KBIBiopharma shared
On Apr 21, 2022
Announcing our new commercial manufacturing facility! "With the highest quality people, systems, and processes, we intend to be a true center of excellence and an exceptional place to work" - Jesse Kingg, SVP & Site Head. Read the full announcement: https://t.co/wvOkBDh467 https://t.co/SySe4X4fTn
Open
KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility

KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility

KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility; Expands US-based mammalian cell culture operations

@biospace shared
On Apr 25, 2022
To discuss what’s likely for 2022, BioSpace caught up with Lance Minor, principal and national co-leader of @BDOhealth. For context, consider these findings from BDO’s recently-published Biotech Brief, Winter 2022. #BDO #Lance Minor #BiotechBrief BioSpace https://t.co/8VkV0b2QqP https://t.co/wvBAPAbLwP
Open
Biotechs Turn to M&A as Liquidity Surges and Market Caps Falter

Biotechs Turn to M&A as Liquidity Surges and Market Caps Falter

Biotech companies are facing sharp declines in stock prices, while venture capital and private equity are experiencing increases. BDO Life Sciences' Lance Minor sat down BioSpace's Gail ...

@biospace shared
On Apr 22, 2022
The COVID-19 pandemic will end one day and, when it does, some biopharma companies will need to revert to a more normal way of working with others. #biopharma #covidnews https://t.co/J0kQKOWEdU
Open
The COVID-19 Pandemic will End, with Implications for Biopharma

The COVID-19 Pandemic will End, with Implications for Biopharma

The COVID-19 pandemic will end one day and, when it does, some biopharma companies will need to revert to a more normal way of working with others.

@biospace shared
On Apr 26, 2022
The first quarter hasn't been kind to international biopharmaceutical firms. BioSpace takes a look at the fates of @Saniona_AB and Black Diamond Therapeutics, read on. #Saniona #BlackDiamondTherapeutics #BioSpace https://t.co/zDbgUbpAqL
Open
Sanonia, Black Diamond Fall Victim To Rough Biotech Market

Sanonia, Black Diamond Fall Victim To Rough Biotech Market

​​​​​​​The first quarter hasn't been kind to international biopharmaceutical firms. BioSpace takes a look at the fates of Saniona and Black Diamond below.

@biospace shared
On Apr 21, 2022
New York-based Terran Biosciences inked a deal with Paris-based @sanofi for two late-stage central nervous system (CNS) assets. Terran plans to advance them for neurological and psychological indications. #neurology #bioscience https://t.co/SmZilsPMbU
Open
Sanofi Strikes Deal With Mysterious Psychedelics Biotech Terran

Sanofi Strikes Deal With Mysterious Psychedelics Biotech Terran

New York-based Terran Biosciences inked a deal with Paris-based Sanofi for two late-stage central nervous system (CNS) assets. Terran plans to advance them for neurological and ...

@matthewherper shared
On Apr 26, 2022
RT @brianreid: The news that Ronny Gal is headed to Novartis is fascinating from a drug-pricing POV. Gal has probably been the most loudest voice on Wall Street on the topic. Some highlights (quick 🧵) https://t.co/o6FxNX3XGv
Open
In a surprise move, Novartis CEO Vas Narasimhan recruits top analyst Ronny Gal as new strategy, BD chief

In a surprise move, Novartis CEO Vas Narasimhan recruits top analyst Ronny Gal as new strategy, BD chief

After a long run observing Novartis and the rest of the Big Pharma world as a top analyst, Bernstein’s Ronny Gal will now move into the upper echelon of the Swiss giant’s executive crew to ...

@biospace shared
On Apr 25, 2022
@Ocugen which has faced a string of delays with its @BharatBiotech-partnered vaccine, reported some good news today. Read on to find out more! #Ocugen #BharatBiotech #BioSpace https://t.co/fsBNEpnX2a
Open
Ocugen Sees Ray of Light with Gene Therapy for Retinitis Pigmentosa

Ocugen Sees Ray of Light with Gene Therapy for Retinitis Pigmentosa

The DSMB for Ocugen's Phase I/II trial of OCU400, a gene therapy in development for Retinitis Pigmentosa (RP), recommended the study proceed with enrolling more patients.

@BioWorld shared
On Apr 26, 2022
Drug developers drop again amid finicky markets https://t.co/rAp3p2nTMZ #biotech #pharma @NektarNews @bluebirdbio @Alkermes @ionispharma
Open
Drug developers drop again amid finicky markets

Drug developers drop again amid finicky markets

While BioWorld’s Drug Developers Index appeared to be moving in the right direction last month, it did an about-face in April and is now at its lowest point this year, down 23.1%, following ...